{"id":"drospirenone-ethinyl-estradiol-myo-inositol","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Breast tenderness"},{"rate":"5-15","effect":"Breakthrough bleeding"},{"rate":"3-5","effect":"Mood changes"},{"rate":"0.3-0.4","effect":"Venous thromboembolism"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Drospirenone (a progestin) and ethinyl estradiol (an estrogen) work synergistically to inhibit the luteinizing hormone (LH) surge and suppress follicle-stimulating hormone (FSH), preventing ovulation. Myo-inositol, an insulin sensitizer, is added to potentially improve ovulatory function, reduce androgen levels, and enhance metabolic outcomes in women with polycystic ovary syndrome (PCOS) or metabolic dysfunction.","oneSentence":"This combination oral contraceptive suppresses ovulation through progestin and estrogen activity while myo-inositol may improve insulin sensitivity and metabolic parameters.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:35:40.974Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contraception"},{"name":"Polycystic ovary syndrome (PCOS) management"},{"name":"Irregular menstrual cycles with metabolic dysfunction"}]},"trialDetails":[{"nctId":"NCT07242131","phase":"NA","title":"Efficacy of Oral Contraceptive, Progesterone, and Inositol on Menstrual Regulation in PCOS","status":"RECRUITING","sponsor":"Ege University","startDate":"2025-12-01","conditions":"Polycystic Ovary Syndrome (PCOS)","enrollment":150},{"nctId":"NCT01511822","phase":"PHASE4","title":"Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance","status":"COMPLETED","sponsor":"AGUNCO Obstetrics and Gynecology Centre","startDate":"","conditions":"PCOS, Polycystic Ovary Syndrome","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Drospirenone Ethinyl estradiol Myo-inositol","genericName":"Drospirenone Ethinyl estradiol Myo-inositol","companyName":"AGUNCO Obstetrics and Gynecology Centre","companyId":"agunco-obstetrics-and-gynecology-centre","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination oral contraceptive suppresses ovulation through progestin and estrogen activity while myo-inositol may improve insulin sensitivity and metabolic parameters. Used for Contraception, Polycystic ovary syndrome (PCOS) management, Irregular menstrual cycles with metabolic dysfunction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}